Colorectal Cancer Market Size, Share, Competitive Landscape, and Trend Analysis Report by Treatment Type, Route of Administration, End User, and Region: Global Opportunity Analysis and Industry Forecast, 2024-2033

The colorectal cancer market was valued at $21.03 billion in 2023 and is estimated to reach $30.95 billion by 2033, exhibiting a CAGR of 4.0% from 2024 to 2033.

Overview of Colorectal Cancer

Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Although treatment has significantly advanced, the exact cause of colorectal cancer remains unclear. Early diagnosis greatly enhances diagnosis, but the disease frequently presents with non-specific or no symptoms in its early stages, resulting in low rates of early detection. Treatment strategies for colorectal cancer depend on the tumor stage and patient characteristics and include surgery, chemotherapy, radiotherapy, molecular targeted therapy, and immunotherapy. Addressing the challenge of early detection and continuing to improve treatment options are critical in reducing the global burden of this disease.

Key Takeaways

• The colorectal cancer market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($billion) for the projected period from 2024 to 2033.
• More than 1,500 product literatures, industry releases, annual reports, and other such documents of major colorectal cancer industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
• The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

Industry Trends

• In May 2024, the FDA has approved ColoSense, a noninvasive multitarget stool RNA test developed by Geneoscopy, Inc., as a screening tool for individuals aged 45 and older at average risk for colorectal cancer (CRC). Geneoscopy announced that the FDA has also designated ColoSense as a Breakthrough Device. This marks the first noninvasive CRC screening test to utilize RNA biomarkers to detect disease activity in this patient population. The approval and designation highlight ColoSense's potential to significantly improve CRC screening and early detection.
• In October 2023, the Colorectal Cancer Alliance launched Project Cure CRC, aiming to invest tens of millions of dollars in expedited, novel colorectal cancer research over the next two years. The initiative's initial $1.6 million funding would support innovative work by Dr. Raghu Kalluri at The University of Texas MD Anderson Cancer Center. His research focuses on developing urgently needed therapeutic options for the 96% of colorectal cancer patients with microsatellite stable (MSS) disease, who currently have limited treatment options. Project Cure CRC's substantial financial resources would enable the Alliance to support numerous similar studies.

Key Market Dynamics

Advancements in the understanding of molecular pathways and genetic alterations driving colorectal cancer have established the path for the development of targeted therapies and personalized treatment approaches. By identifying specific genetic mutations and molecular mechanisms, researchers can design treatments that directly target these abnormalities, improving the efficacy and precision of cancer therapies. This personalized approach allows for innovative treatment plans based on an individual's unique genetic profile, enhancing the potential for better outcomes and reducing the likelihood of adverse effects. Consequently, these innovations represent a significant shift towards more effective and individualized colorectal cancer management.

However, despite advancements in targeted therapies and immunotherapy, resistance mechanisms develop, limiting treatment efficacy and necessitating alternative approaches. Acquired resistance to chemotherapy agents and molecularly targeted drugs presents significant challenges in managing advanced colorectal cancer, highlighting the need for ongoing R&D of novel treatments.

The emergence of advanced diagnostic technologies like liquid biopsy, next-generation sequencing, and imaging modalities enhances early detection, prognostication, and treatment monitoring, driving the colorectal cancer market expansion. These innovations significantly improve patient outcomes by enabling more precise and timely interventions.

Patent Analysis

Market Segmentation

The colorectal cancer market is segmented into treatment type, route of administration, end user, and region. On the basis of treatment type, the market is divided into chemotherapy, targeted therapy, radiation therapy, surgery, immunotherapy, and others. As per route of administration, the market is classified into oral, parenteral, and others. Based on end user, the market is divided into homecare, specialty clinics, hospitals, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Country Market Outlook

The increasing number of colorectal cancer patients in China is expected to drive significant market growth. Colorectal cancer cases in China have increased due to lifestyle changes, aging population, and dietary habits. According to the World Health Organization (WHO), the incidence of colorectal cancer in China has increased by nearly 40% over the past decade, with an estimated 550,000 new cases reported annually. This alarming trend highlights the urgent need for improved diagnostic and treatment solutions, driving growth of the colorectal cancer market. Enhanced healthcare infrastructure and government initiatives to boost cancer awareness and early detection are also contributing to market expansion in China. As the number of patients continues to rise, the market for colorectal cancer diagnostics, therapeutics, and supportive care is expected to witness robust growth, providing substantial opportunities for industry stakeholders to innovate and cater to this rising medical need.

• In July 2020, Taiho Pharmaceutical Co., Ltd. launched LONSURF (trifluridine/tipiracil, TAS-102) in Japan for metastatic colorectal cancer (mCRC) patients who have undergone prior chemotherapy, and potentially treated or unable to be treated with anti-VEGF or anti-EGFR therapies. Approved in China in August 2019, LONSURF's approval was based on the Phase III TERRA study, which demonstrated a statistically significant improvement in overall survival (OS) in refractory mCRC patients from China, South Korea, and Thailand.

Competitive Landscape

The major players operating in the colorectal cancer market include Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer AG, Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC, Novartis International AG, Pfizer Inc., and Sanofi.

Other players in the colorectal cancer market include AbbVie Inc. and Takeda Pharmaceutical Company Limited.

Recent Key Strategies and Developments

• In November 2023, Guardant Health, Inc., a precision oncology company, launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. Colorectal cancer (CRC), a leading cancer and the third-leading cause of cancer deaths in South Korea, can now be detected early with Shield. This innovative test analyzes circulating tumor DNA (ctDNA) shed by tumors into the bloodstream. In the pivotal ECLIPSE study, involving over 20,000 patients, Shield achieved 83% sensitivity and 90% specificity for detecting colorectal cancer in average-risk adults in the U.S. Shield is now available for regular CRC screening in eligible individuals.

Key Sources Referred

1. American Cancer Society
2. Colorectal Cancer Alliance
3. Guardant Health, Inc.
4. Taiho Pharmaceutical Co., Ltd.
5. FDA

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the colorectal cancer market segments, current trends, estimations, and dynamics of the colorectal cancer market analysis from 2023 to 2033 to identify the prevailing colorectal cancer market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the colorectal cancer market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global colorectal cancer market statistics.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

Apart from the points mentioned above, the report includes the analysis of the regional as well as global colorectal cancer market trends, key players, market segments, application areas, and market growth strategies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation

1.5.1. Top-down approach
1.5.2. Bottom-up approach

2. Report Scope

2.1. Market definition
2.2. Key objectives of the study
2.3. Market segmentation

3. Executive Summary
4. Market Overview

4.1. Introduction
4.2. Growth impact forces

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities

4.3. Market value chain analysis

4.3.1. List of service provider

4.4. Innovation & sustainability matrices

4.4.1. Technology matrix
4.4.2. Patent matrix
4.4.3. Regulatory matrix

4.5. Porter’s five forces analysis

4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive Rivalry Intensity

4.6. PESTLE analysis

4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Legal
4.6.6. Environmental

5. Cold Plasma Market Analysis, by Regime

5.1. Overview
5.2. Atmospheric Pressure

5.2.1. Definition, key trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2023-2033
5.2.3. Market share analysis, by country, 2023-2033

5.3. Low Pressure

5.3.1. Definition, key trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2023-2033
5.3.3. Market share analysis, by country, 2023-2033

5.4. Research Dive Exclusive Insights

5.4.1. Market attractiveness
5.4.2. Competition heatmap

6. Cold Plasma Market Analysis, by Application

6.1. Overview
6.2. Surface Treatment

6.2.1. Definition, key trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2023-2033
6.2.3. Market share analysis, by country, 2023-2033

6.3. Sterilization & Disinfection

6.3.1. Definition, key trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2023-2033
6.3.3. Market share analysis, by country, 2023-2033

6.4. Coating & Finishing

6.4.1. Definition, key trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2023-2033
6.4.3. Market share analysis, by country, 2023-2033

6.5. Adhesion

6.5.1. Definition, key trends, growth factors, and opportunities
6.5.2. Market size analysis, by region, 2023-2033
6.5.3. Market share analysis, by country, 2023-2033

6.6. Wound Healing 

6.6.1. Definition, key trends, growth factors, and opportunities
6.6.2. Market size analysis, by region, 2023-2033
6.6.3. Market share analysis, by country, 2023-2033

6.7. Others

6.7.1. Definition, key trends, growth factors, and opportunities
6.7.2. Market size analysis, by region, 2023-2033
6.7.3. Market share analysis, by country, 2023-2033

6.8. Research Dive Exclusive Insights

6.8.1. Market attractiveness
6.8.2. Competition heatmap

7. Cold Plasma Market Analysis, by End User

7.1. Overview
7.2. Automotive

7.2.1. Definition, key trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2023-2033
7.2.3. Market share analysis, by country, 2023-2033

7.3. Electronics & Semiconductors

7.3.1. Definition, key trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2023-2033
7.3.3. Market share analysis, by country, 2023-2033

7.4. Food Processing & Packaging

7.4.1. Definition, key trends, growth factors, and opportunities
7.4.2. Market size analysis, by region, 2023-2033
7.4.3. Market share analysis, by country, 2023-2033

7.5. Healthcare

7.5.1. Definition, key trends, growth factors, and opportunities
7.5.2. Market size analysis, by region, 2023-2033
7.5.3. Market share analysis, by country, 2023-2033

7.6. Aerospace

7.6.1. Definition, key trends, growth factors, and opportunities
7.6.2. Market size analysis, by region, 2023-2033
7.6.3. Market share analysis, by country, 2023-2033

7.7. Others

7.7.1. Definition, key trends, growth factors, and opportunities
7.7.2. Market size analysis, by region, 2023-2033
7.7.3. Market share analysis, by country, 2023-2033

7.8. Research Dive Exclusive Insights

7.8.1. Market attractiveness
7.8.2. Competition heatmap

8. Cold Plasma Market, by Region

8.1. North America

8.1.1. U.S.

8.1.1.1. Market size analysis, by Regime, 2023-2033
8.1.1.2. Market size analysis, by Application, 2023-2033
8.1.1.3. Market size analysis, by End User, 2023-2033

8.1.2. Canada

8.1.2.1. Market size analysis, by Regime, 2023-2033
8.1.2.2. Market size analysis, by Application, 2023-2033
8.1.2.3. Market size analysis, by End User, 2023-2033

8.1.3. Mexico

8.1.3.1. Market size analysis, by Regime, 2023-2033
8.1.3.2. Market size analysis, by Application, 2023-2033
8.1.3.3. Market size analysis, by End User, 2023-2033

8.1.4. Research Dive Exclusive Insights

8.1.4.1. Market attractiveness
8.1.4.2. Competition heatmap

8.2. Europe

8.2.1. Germany 

8.2.1.1. Market size analysis, by Regime, 2023-2033
8.2.1.2. Market size analysis, by Application, 2023-2033
8.2.1.3. Market size analysis, by End User, 2023-2033

8.2.2. UK

8.2.2.1. Market size analysis, by Regime, 2023-2033
8.2.2.2. Market size analysis, by Application, 2023-2033
8.2.2.3. Market size analysis, by End User, 2023-2033

8.2.3. France

8.2.3.1. Market size analysis, by Regime, 2023-2033
8.2.3.2. Market size analysis, by Application, 2023-2033
8.2.3.3. Market size analysis, by End User, 2023-2033

8.2.4. Spain

8.2.4.1. Market size analysis, by Regime, 2023-2033
8.2.4.2. Market size analysis, by Application, 2023-2033
8.2.4.3. Market size analysis, by End User, 2023-2033

8.2.5. Italy

8.2.5.1. Market size analysis, by Regime, 2023-2033
8.2.5.2. Market size analysis, by Application, 2023-2033
8.2.5.3. Market size analysis, by End User, 2023-2033

8.2.6. Rest of Europe

8.2.6.1. Market size analysis, by Regime, 2023-2033
8.2.6.2. Market size analysis, by Application, 2023-2033
8.2.6.3. Market size analysis, by End User, 2023-2033
8.2.7. Research Dive Exclusive Insights

8.2.7.1. Market attractiveness
8.2.7.2. Competition heatmap

8.3. Asia-Pacific

8.3.1. China

8.3.1.1. Market size analysis, by Regime, 2023-2033
8.3.1.2. Market size analysis, by Application, 2023-2033
8.3.1.3. Market size analysis, by End User, 2023-2033

8.3.2. Japan 

8.3.2.1. Market size analysis, by Regime, 2023-2033
8.3.2.2. Market size analysis, by Application, 2023-2033
8.3.2.3. Market size analysis, by End User, 2023-2033

8.3.3. India

8.3.3.1. Market size analysis, by Regime, 2023-2033
8.3.3.2. Market size analysis, by Application, 2023-2033
8.3.3.3. Market size analysis, by End User, 2023-2033

8.3.4. Australia

8.3.4.1. Market size analysis, by Regime, 2023-2033
8.3.4.2. Market size analysis, by Application, 2023-2033
8.3.4.3. Market size analysis, by End User, 2023-2033

8.3.5. South Korea
8.3.5.1. Market size analysis, by Regime, 2023-2033
8.3.5.2. Market size analysis, by Application, 2023-2033
8.3.5.3. Market size analysis, by End User, 2023-2033

8.3.6. Rest of Asia-Pacific

8.3.6.1. Market size analysis, by Regime, 2023-2033
8.3.6.2. Market size analysis, by Application, 2023-2033
8.3.6.3. Market size analysis, by End User, 2023-2033

8.3.7. Research Dive Exclusive Insights

8.3.7.1. Market attractiveness
8.3.7.2. Competition heatmap

8.4. LAMEA

8.4.1. Brazil

8.4.1.1. Market size analysis, by Regime, 2023-2033
8.4.1.2. Market size analysis, by Application, 2023-2033
8.4.1.3. Market size analysis, by End User, 2023-2033

8.4.2. UAE

8.4.2.1. Market size analysis, by Regime, 2023-2033
8.4.2.2. Market size analysis, by Application, 2023-2033
8.4.2.3. Market size analysis, by End User, 2023-2033

8.4.3. Saudi Arabia

8.4.3.1. Market size analysis, by Regime, 2023-2033
8.4.3.2. Market size analysis, by Application, 2023-2033
8.4.3.3. Market size analysis, by End User, 2023-2033

8.4.4. South Africa

8.4.4.1. Market size analysis, by Regime, 2023-2033
8.4.4.2. Market size analysis, by Application, 2023-2033
8.4.4.3. Market size analysis, by End User, 2023-2033

8.4.5. Rest of LAMEA

8.4.5.1. Market size analysis, by Regime, 2023-2033
8.4.5.2. Market size analysis, by Application, 2023-2033
8.4.5.3. Market size analysis, by End User, 2023-2033

8.4.6. Research Dive Exclusive Insights

8.4.6.1. Market attractiveness
8.4.6.2. Competition heatmap

9. Competitive Landscape

9.1. Top winning strategies, 2022

9.1.1. By strategy
9.1.2. By year

9.2. Strategic overview
9.3. Market share analysis, 2022

10. Company Profiles

10.1. Apyx Medical

10.1.1. Overview
10.1.2. Business segments
10.1.3. Product portfolio
10.1.4. Financial performance
10.1.5. Recent developments
10.1.6. SWOT analysis

10.2. AcXys Plasma Technologies

10.2.1. Overview
10.2.2. Business segments
10.2.3. Product portfolio
10.2.4. Financial performance
10.2.5. Recent developments
10.2.6. SWOT analysis

10.3. Enercon Industries Corporation

10.3.1. Overview
10.3.2. Business segments
10.3.3. Product portfolio
10.3.4. Financial performance
10.3.5. Recent developments
10.3.6. SWOT analysis

10.4. Adtec Plasma Technology Co., Ltd.

10.4.1. Overview
10.4.2. Business segments
10.4.3. Product portfolio
10.4.4. Financial performance
10.4.5. Recent developments
10.4.6. SWOT analysis

10.5. Henniker Plasma

10.5.1. Overview
10.5.2. Business segments
10.5.3. Product portfolio
10.5.4. Financial performance
10.5.5. Recent developments
10.5.6. SWOT analysis

10.6. Coating Plasma Innovation

10.6.1. Overview
10.6.2. Business segments
10.6.3. Product portfolio
10.6.4. Financial performance
10.6.5. Recent developments
10.6.6. SWOT analysis

10.7. Nordson Corporation

10.7.1. Overview
10.7.2. Business segments
10.7.3. Product portfolio
10.7.4. Financial performance
10.7.5. Recent developments
10.7.6. SWOT analysis

10.8. Europlasma N.V.

10.8.1. Overview

10.8.2. Business segments
10.8.3. Product portfolio
10.8.4. Financial performance
10.8.5. Recent developments
10.8.6. SWOT analysis

10.9. P2i Limited 

10.9.1. Overview
10.9.2. Business segments
10.9.3. Product portfolio
10.9.4. Financial performance
10.9.5. Recent developments
10.9.6. SWOT analysis

10.10. Plasmatreat GmbH

10.10.1. Overview
10.10.2. Business segments
10.10.3. Product portfolio
10.10.4. Financial performance
10.10.5. Recent developments
10.10.6. SWOT analysis

* Taxes/Fees, If applicable will be added during checkout. All prices in USD.